Contact
searchSearch
HMP Global
Login
Paolo Tarantino, MD
Videos
Sacituzumab Govitecan Demonstrates Limited Activity Following T-DXd in HER2-Positive Metastatic Breast Cancer
05/07/2026
Paolo Tarantino, MD, PhD
Paolo Tarantino, MD, discusses results from the phase 2 SATEEN trial evaluating sacituzumab govitecan plus trastuzumab in heavily pretreated patients with HER2-positive metastatic breast cancer.
Paolo Tarantino, MD, discusses results from the phase 2 SATEEN trial evaluating sacituzumab govitecan plus trastuzumab in heavily pretreated patients with HER2-positive metastatic breast cancer.
Paolo Tarantino, MD, discusses...
05/07/2026
Oncology
News
Giredestrant Demonstrates Antiproliferative Activity in Premenopausal Patients With Early Breast Cancer
05/07/2026
Stephanie Holland
Results from the phase 2 PREcoopERA trial demonstrated that giredestrant shows antiproliferative activity in premenopausal ER-positive, HER2-negative early breast cancer.
Results from the phase 2 PREcoopERA trial demonstrated that giredestrant shows antiproliferative activity in premenopausal ER-positive, HER2-negative early breast cancer.
Results from the phase 2...
05/07/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use